ASCENDIS PHARMA a/S

Ascendis Pharma’s new Russell index inclusion boosts visibility and attracts passive funds, while its upcoming ICCBH 2026 achondroplasia presentation positions the biotech firm for growth in rare‑disease therapy.

Ascendis Pharma unveils breakthrough achondroplasia trial results at ICCBH 2026, highlighting TransCon CNP/​hGH therapy advances and promising skeletal‑health outcomes.